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Reverse signalingImmunosuppressive cytotoxic T lymphocyte associated antigen-4 immunoglobulin fusion proteins (CTLA4-Ig)
block the CD28:CD80/86 costimulatory pathway. On a cellular level, CTLA4-Ig is understood to dampen T cell re-
sponses. As a mechanism, CTLA4-Ig has been reported to affect dendritic cell (DC) function via inducing the im-
munosuppressive indoleamine 2,3 dioxygenase (IDO) pathway and promoting a DC regulatory phenotype. We
here probed cellular mechanisms of CTLA4-Ig immunoregulation in an allogeneic setting using C57BL/6 splenic
or bone marrow derived DCs (BMDCs) as stimulators of allogeneic Balb/c derived T cells. To address whether
CTLA4-Ig immunosuppression affected DCs, we pre-exposed C57BL/6 splenic or BMDCs to CTLA4-Ig and re-
moved unbound CTLA4-Ig before co-culture with allogeneic T cells. CTLA4-Ig disappeared rapidly (within 4 h)
from the cell membrane by combined internalization and dissociation. These CTLA4-Ig pre-exposed DCs were
fully capable of stimulating allogeneic T cell proliferation, suggesting that CTLA4-Ig does not impair the DC stim-
ulatory capacity. Only the presence of CTLA4-Ig during DC/T cell co-culture resulted in the expected inhibition of
proliferation. C57BL/6 splenic or BMDCs exposed to CTLA4-Ig did not display IDO activity. We conclude that
CTLA4-Ig immunosuppressive activity does not depend on a DC regulatory phenotype but on its presence during
DC/T cell interaction.
© 2013 Elsevier B.V. Open access under CC BY-NC-ND license. 1. Introduction
Amajor task in transplantation research, including solid organ trans-
plantation (SOT) and hematopoietic stem cell transplantation (HSCT), is
to rapidly achieve a state of allo-speciﬁc tolerance. T cells play a key role
in regulating transplantation immunology. Allo-speciﬁc T cell tolerance
implies that T cells do notmount pathogenic immune reactions towards
allogeneic organs but preserve protective activity towards environmen-
tal pathogens. Thus, allo-speciﬁc tolerized T cells are critical to
accomplishing transplantation tolerance.
T cells, in order tomount appropriate responses upon antigen recog-
nition, need to receive costimulatory signals. Costimulatory signaling
involves a multitude of costimulatory molecules present on antigen-
presenting cells (APCs) interacting with their appropriate receptors on
T cells to ﬁnally optimize T cell proliferation and cytokine secretion
(reviewed in [1]). Previous studies have shown that antigen stimulation
of T cells in the absence of costimulation will leave T cells anergic, i.e.
unresponsive to subsequent stimulation by the same antigen [2–4].
The most extensively studied costimulatory pathway required for the
induction of full T cell immune responses is the interaction of CD80h Institute, Zimmermannplatz
x: +43 1 470 64070.
.
-ND license. and CD86 molecules expressed on dendritic cells (DCs) with the CD28
molecule expressed on T cells, which provides signals for proliferation
and survival. Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is
expressed by activated T cells and mediates a T cell inhibitory signal
to limit excess T cell stimulation. CTLA-4 immunoglobulin fusion pro-
teins (CTLA4-Ig) have been pharmacologically engineered to block
CD28-mediated costimulatory signaling to T cells to induce tolerance
[5]. CTLA4-Ig consists of the extracellular binding domain of CTLA-4
linked to an Fc domain of IgG and possesses a high binding afﬁnity to
CD80 and CD86 (reviewed in [6,7]).
CTLA4-Ig pharmacological compounds (abatacept, belatacept)
have been introduced to the clinic as a treatment of autoimmune dis-
ease, such as rheumatoid arthritis [8] and to prevent organ rejection
in kidney transplantation [9]. The precise cellular mechanisms of
tolerogenesis by CTLA4-Ig are still a matter of research. A recently
proposed model suggested that CTLA4-Ig binding to CD80/CD86 mol-
ecules provided a ‘reverse’ signal to DCs resulting in the induction of
the immunomodulatory enzyme indoleamine 2,3 dioxygenase (IDO)
[10,11]. IDO is the major and rate limiting enzyme of tryptophan me-
tabolism in mammals initiating tryptophan metabolism along the
kynurenine pathway [12]. IDO augmented activity is preferentially
expressed in antigen-presenting cells, such as DCs, and interferes
with the T cell proliferative capacity [13,14] and promotes T cell apo-
ptotic decline [15]. Thus, IDO activity in DCs has been proposed to
possess powerful immune regulatory and tolerance inducing capacity
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suggested to underlie the tolerogenic capacity of CTLA4-Ig [10,18].
In the present study, we set out to improve the understanding of
the effects of CTLA4-Ig on a cellular level. Our ﬁndings, unexpectedly,
provide evidence that immunoregulation by CTLA4-Ig does not re-
quire IDO activity or the induction of a DC regulatory phenotype; in-
stead, CTLA4-Ig mediated regulation of allogeneic T cell proliferation
by directly interfering with DC/T cell interaction.
2. Materials and methods
2.1. Mice and reagents
Female C57BL/6 (H-2b) and Balb/c (H-2d) mice (Charles River
Laboratories, Sulzfeld, Germany), aged six to 10 weeks, were
maintained under speciﬁc pathogen-free conditions at the Biomedical
Research Institute, Medical University of Vienna (Austria). All exper-
iments were approved by the institutional review board and followed
the national and international guidelines of laboratory animal care.
CTLA4-Ig fusion protein (IgG1) (abatacept) [19,20] was kindly
provided by Bristol-Meyers Squibb Pharmaceuticals (Princeton, NJ,
USA).
2.2. Cell culture medium
All assays were performed in IMDM (Invitrogen, Carlsbad, CA,
USA) containing 2 mM L-glutamin and 25 mM Hepes supplemented
with 10% FBS (PAA Laboratories, Pasching, Austria), antibiotics and
50 μM 2-mercaptoethanol (Sigma, St. Louis, MO, USA), hereafter
termed complete medium. Cell cultures were maintained in humidi-
ﬁed air containing 5% CO2 at 37 °C.
2.3. Cell preparation
Splenic DCs were enriched from C57BL/6 mice following previously
described protocols [10,21]. In brief, spleens were injected with collage-
nase (type IV, 100 U/ml, Sigma) and placed in collagenase IV (400 U/ml)
solution for 30 min at 37 °C and made into single cell suspensions.
Single cells were recovered in 50% isoosmotic Nycodenz solution
(Sigma), and centrifuged at 450 g. The low density fractionwas adhered
for 2 h and non-adherent cells were removed. After further 18 h, the de-
tached cells were recovered. Alternatively, DCs were enriched by mag-
netic cell sorting (MACS) using CD11c selection columns (Miltenyi
Biotec, Bergisch-Gladbach, Germany).
Bone marrow (BM) derived DCs (BMDCs) were generated from
mouse BM as previously described [22]. DC populations were identi-
ﬁed by co-expression of CD11c and CD11b; either procedure yielded
~90% CD11c+ cells.
For examining the effect of CTLA4-Ig, splenic DCs (1×106/ml per
well) were plated in 24-well culture plates (IWAKI Europe, Willich,
Germany) and exposed to CTLA4-Ig (40 μg/ml) [10] for 24 h. BMDCs
were activated with LPS (Escherichia coli O111:B4, Calbiochem, San
Diego, CA) and IFN-γ (BD Biosciences, San Diego, CA, USA) for 48 h
as indicated. The DC phenotype was examined for MHC class I and
class II, and CD80 and CD86 expression. T cells were enriched from
Balb/c spleens using the Pan T Cell Isolation Kit (MACS; Miltenyi
Biotec), routinely yielding >95% CD3+ cells.
2.4. T cell stimulation and mixed lymphocyte reaction (MLR)
CD3+T cells (1×105)were co-culturedwith allogeneicDCs (1×104)
for 3 to 6 d in 96-well round bottom plates (NUNC, Thermo Fisher,
Rochester, NY, USA) in triplicates in 200 μl complete medium per well
(MLR). For DC independent T cell proliferation assays, CD3+ T cells
(1×105) were stimulated with 3 μg/ml immobilized anti-CD3 and
1 μg/ml anti-CD28 (BD Biosciences) for 48 h.T cell proliferation was assessed by CFSE (Sigma) dilution as pre-
viously described [23]. Inhibition of proliferation was calculated
as follows: Percent inhibition=[1−(percent CFSE− T cells in co-
cultures with CTLA4-Ig/percent CFSE− T cells in co-cultures without
CTLA4-Ig)]×100.
2.5. Flow cytometry
Flow cytometric examinations were performed using a FACSCalibur
or a BD LSR II ﬂow cytometer (BD Biosciences). List mode data were an-
alyzed using either FACSDiva (BD Biosciences) or FlowJo (Tree Star,
Ashland, OR, USA) software. The followingAbswere used: unconjugated
anti-CD16/32 (2.4G2), FITC-anti-H-2Db (KH95), PE-anti-I-Ab (AF6-
120.1), PE-Cy7-anti-CD11c (HL3), APC-Cy7-anti-CD11b (M1/70), APC-
anti-CD3 (145-2C11), PerCP-anti-CD4 (RM4-5), PE-Cy7-anti-CD25
(PC61) (all from BD Biosciences), PerCP/Cy5.5-anti-CD80 (16-10A1)
and Alexa Fluor 700-anti-CD86 (PO3) (all from BioLegend, San Diego,
CA, USA).
2.6. Enzyme linked immunosorbent assay (ELISA)
Splenic DCs or BMDCs (1×106/ml) were incubated with or without
LPS (100 ng/ml), CTLA4-Ig (50 μg/ml) and/or human IgG1 (50 μg/ml)
(Sigma) for 24 h. Interferon-gamma (IFN-γ) was measured in culture
supernatants by ELISA (BD OptEIA mouse IFN-γ ELISA set, BD Biosci-
ences), or mouse IFN-γ ELISA (Ready-SET-Go!, eBiosciences, San Diego,
CA, USA). Optical densities were analysed using an EnSpire reader
(PerkinElmer, Waltham, MA, USA).
2.7. Immunoblotting
IDO protein expression in DCs was investigated using a rabbit
anti-mouse IDO polyclonal Ab kindly provided by O. Takikawa
(National Institute for Longevity Sciences, National Center for Geriatrics
and Gerontology, Japan) [24]. Mouse monoclonal anti-mouse GAPDH
antibody (Ambion, Austin, TX, USA) was used as an internal control.
Ab binding was visualized using the Odyssey Infrared Imaging System
(Odyssey Classic, LI-COR Biosciences, Lincoln, NE, USA) and the respec-
tive ﬂuorescent secondary Abs: goat anti-rabbit IgG, DyLight800
conjugated and goat anti-mouse IgG, DyLight680 conjugated (Pierce
Biotechnology, Rockford, IL, USA). Densitometric analysis was done
using the ImageJ freeware (NIH, Bethesda, MD, USA).
2.8. IDO mRNA detection
Expression levels of IDO transcript in DCswere determined by semi-
quantitative RT-PCR. In brief, total RNA was isolated from cells with the
use of Trizol reagent (Invitrogen, Lofer, Austria). RNA was reversely
transcribed with 200 Units Moloney-murine leukemia virus RT
(Invitrogen) and 100 pmol random hexamers (GE Healthcare, Vienna,
Austria) at 42 °C for 1 h. RT-PCRwas performed using Hot Start Taq po-
lymerase (Qiagen, Vienna, Austria) with an initial activation step at
95 °C for 14 min according to the manufacturer's instructions.
Cycling conditions were as follows: denaturation at 95 °C for 30 s,
annealing at 60 °C for 30 s, and elongation at 72 °C for 1 min. 35 cy-
cles were followed by a ﬁnal extension at 72 °C for 7 min.
Oligonucleotides (MWG Biotech AG, Ebersberg, Germany) used for
ampliﬁcation of the murine IDO or of the murine GAPDH were as fol-
lows: IDO, 5′-CGACATAGCTACCA GTCTGGAGAAAG-3′ and 5′-GCGAGG
TGGAACTTTCTCACAGAG-3′; GAPDH, 5′-AC CACAGTCCATGCCATCAC-3′
and 5′-TCCACCACCCTGTTGCTGTA-3′. Ampliﬁcation products were size-
fractionated by agarose gel electrophoresis on a 1% agarose gel, stained
with ethidium bromide and quantiﬁed by scanning densitometry
(Gel-Doc 1000, Molecular Analyst Software, Biorad, Hercules, CA, USA).
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Fig. 1. Effect of CTLA4-Ig on costimulatory molecule expression in C57BL/6 splenic and
BMDCs. Splenic DCs (left column) were incubated for 24 h with CTLA4-Ig (40 μg/ml).
BMDCs (middle, right column) were incubated for 24 h without or with LPS stimula-
tion (100 ng/ml) and were subsequently exposed to CTLA4-Ig (100 μg/ml, 2 h). After
washing, DCs were stained for MHC class I and II, CD80 and CD86 and analyzed by
ﬂow cytometry. Shaded histograms, isotype control; open histograms, DCs without
(dotted line) or with (black line) CTLA4-Ig. MFI, mean ﬂuorescence intensity. One rep-
resentative experiment of 3 experiments is shown.
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IDO enzymatic activity was determined by measuring the levels of
tryptophan and kynurenine in the cell culture supernatants by HPLC
as described [25]. Synthesis of the stable NO metabolite nitrite (NO2−)
was determined in the cell-free culture supernatants by the Griess reac-
tion assay [26]. In brief, sulfanilamide was quantitatively converted to a
diazonium salt through reactionwithNO2− (present in samples) in acid
(phosphoric acid) conditions. The diazonium salt was then coupled to
N(1-naphthyl) ethylenediamine dihydrochloride (NED), forming an
azo dye that was read at 540 nm in a spectrophotometer.
2.10. CTLA4-Ig internalization/dissociation
C57BL/6 BMDCs identiﬁed as CD11c+ DCs were incubated with
CTLA4-Ig (10–100 μg/ml) for 30 min at 4 °C. After twowash procedures,
DCswere incubated 2, 4 and 16 h at 37 °C and 4 °C to allow and dampen
receptor turnover, respectively, thus estimating internalization and dis-
sociation [27]. Subsequently, DCwere thoroughly washed and incubated
with a PE-conjugated AfﬁniPure F(ab′)2 fragment donkey anti-human
IgG antibody (Jackson ImmunoResearch Lab Inc., West Grove, PA, USA)
for 30 min at 4 °C andwere examinedbyﬂowcytometry. Themeanﬂuo-
rescence intensity (MFI) of CTLA4-Ig-IgG (PE)was examined to quantita-
tively estimate the presence of CTLA4-Ig on the DC surface. In parallel,
DCs were incubated with total human IgG (Beriglobin P, ZLB Behring
GmbH, Vienna, Austria) and subjected to the same procedure to deter-
mine the extent of unspeciﬁc Fc binding [28].
2.11. Statistical analysis
All statistical analyses were performed with the Student t test
(paired, 2-tailed). A P-valueb0.05 was considered to indicate statistical
signiﬁcance.
3. Results
3.1. CTLA4-Ig binds to CD80/86 in C57BL/6 splenic and BMDCs
CD11c+ DCs enriched from C57BL/6 spleens displayed a mature
phenotype, indicated by MHC class I/II expression and by constitutive
expression of high levels of the costimulatory molecules CD80 and
CD86 [29,30]. Exposure of these DCs to CTLA4-Ig reduced the detect-
ability of costimulatory CD80 and CD86 molecules with the notion
that CTLA4-Ig particularly bound to the CD80 epitope (Fig. 1, left
panel) [31]. Consistent with the speciﬁcity of CTLA4-Ig, no effect
was observed on the expression levels of MHC class I/II molecules.
The pattern of co-stimulatory molecule expression in BMDCs was
different. In the unstimulated CD11c+ BMDC population only a fraction
expressed CD80 and CD86 costimulatory molecules. As expected, stim-
ulation with LPS increased the levels of MHC class I and class II expres-
sion and, in parallel, the CD11c+ population showed particularly
increased levels of expression of both CD80 and CD86 costimulatory
molecules. Exposing BMDCs to CTLA4-Ig reduced the detectability of
CD80 and CD86 in unstimulated as well as in stimulated DCs, indicating
that CTLA4-Ig effectively prevented CD80 and CD86 antibodies from
binding to their epitopes (Fig. 1, middle and right panel).
3.2. Upon removal from the microenvironment, CTLA4-Ig rapidly
disappears from DC surface
To assesswhether after binding to CD80/86 CTLA4-Ig is stably present
at the surface of DCs, we examined the time course of CTLA4-Ig's
detectability on the DC membrane considering cellular uptake by recep-
tor turnover and dissociation. To pursue this question, we devised an ex-
periment, in which we incubated C57BL/6 BMDCs with CTLA4-Ig and
either maintained DCs at 37 °C to estimate cellular uptake or exposedthe DCs to the cold (4 °C) to dampen receptor turnover and estimate
CTLA4-Ig dissociation [27]. At the indicated time points we assessed the
quantity of CTLA4-Ig present at the DC surface by measuring the MFI of
a PE labeled anti-IgG molecule by ﬂow cytometry.
To ascertain that the PE labeled anti-IgG antibody speciﬁcally de-
tects CTLA4-Ig bound to CD80 or CD86molecules, cells were incubated
with or without CTLA4-Ig or human immunoglobulin (Beriglobin,
100 μg/ml) at 37 °C and then labeled with the PE labeled anti-IgG
antibody. Flow cytometric analyses revealed that staining with the
PE labeled anti-IgG antibody only was barely detectable at the DC
surface and after pre-exposure to total IgG was 50% lower than upon
exposure to CTLA4-Ig, thus reassuring the detectability of speciﬁc
binding (Supplementary Fig. S1).
Next, to evaluate internalization by receptor turnover, we incubated
DCs with CTLA4-Ig for 30 min at 4 °C to allow binding and thenwashed
the cells extensively. Subsequently, DCswere incubated at 37 °C for 4 h
to allow CTLA4-Ig uptake by receptor turnover. Flow cytometric analy-
ses revealed a rapid decrease of theMFI of PE-labeled anti-IgG antibody,
which dropped bymean 52%, 63% and 80% after 2, 4 and 16 h of culture,
respectively (n=3), after removing CTLA4-Ig from the cellular micro-
environment. This observation is consistent with a rapid internalization
of a major proportion of CTLA4-Ig (Fig. 2A, B).
To examine a potential passive dissociation of CTLA4-Ig from the DC
surface, DCs were exposed to CTLA4-Ig and extensively washed as
above and incubated for 4 h at 4 °C. Since low temperatures are known
to dampen receptor turnover, a reduction of the cell-surface located
0 2 4
0
5 000
10 000
15 000
20 000
16
dissociation
uptake
time (hours)
M
FI
A
B
C
CD80 CD86
BMDCs + LPS
0h
2h
16h
uptake dissociation
M
FI
16522
3064
18941
10027
CTLA4-Ig::IgG-PE
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bound PE-labeled anti-IgG antibody dropped by mean 22%, 45% and 75%
at 2, 4 and 16 h, respectively (n=3), after removing CTLA4-Ig (Fig. 2A, B).
Finally, to address the kinetics of re-expression of CD80 and CD86
after blockade, we exposed DCs to CTLA4-Ig and washed them as
above and re-examined the levels of CD80 and CD86 expression at 2
and 16 h later. Remarkably, the levels of expression of CD80 and
CD86 of CTLA4-Ig exposed DCs were comparable to DCs that had not
been exposed to CTLA4-Ig already 2 h after removing CTLA4-Ig from
the microenvironment, indicating that the expression of costimulatory
molecules is rapidly restored once CTLA4-Ig is removed (Fig. 2C).
Taken together, the results indicated that (i) the major portion of
bound CTLA4-Ig disappeared from the DC surface within 2–4 h after
removal of unbound CTLA4-Ig from the cellular microenvironment
by combined receptor turnover and dissociation and that (ii) the
DCs rapidly recovered the costimulatory signaling apparatus.
3.3. CTLA4-Ig does not stimulate DCs to acquire IDO competence
So far, the ﬁndings suggested that binding of CTLA4-Ig to CD80/86
at the DC surface is short-lived. To explore a potential signaling effectof CTLA4-Ig to DCs [10,32], we tested whether CTLA4-Ig stimulated
IFN-γ production [32] which was reported to be linked to expression
and activity of the tryptophan metabolizing and immunosuppressive
enzyme IDO [10] by DCs.
We ﬁrst observed that a 24-hour exposure of splenic DCs to
CTLA4-Ig resulted in a slight increase of IFN-γ secretion (~200 pg/ml,
mean of 3 experiments), similar to a previous report [32] (Fig. 3, left
panel). In contrast, in BMDCs, IFN-γ releasewas inducible only by expo-
sure to LPS but remained undetectable when BMDCs were exposed to
50 μg/ml CTLA4-Ig (Fig. 3, right panel) and even when the dose of
CTLA4-Ig was increased up to 100 μg/ml (not shown). As well, a
human IgG1 isotype binding solely to DC Fc receptors was unable to
stimulate DC IFN-γ production. Together, the ﬁndings indicate that
the ability of CTLA4-Ig to stimulate low-level IFN-γ secretion was re-
stricted to splenic DCs.
As our ﬁndings did not consistently support the concept of CTLA4-Ig
stimulated DC IFN-γ production, in a next step, we straightforwardly in-
vestigated whether CTLA4-Ig induced IDO expression and activity. Our
data did not support this concept. In splenic DCs, consistentwith previous
reports [33], some basal levels of expression of IDOmRNAwere detected
by RT-PCR even in the absence of CTLA4-Ig (Fig. 4A, upper panel). These
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DCs to CTLA4-Ig. Likewise, baseline levels of IDO protein expression de-
tectable by immunoblotting [32] remained at the same level upon expos-
ing DCs to CTLA4-Ig (Fig. 4A, lower panel). In consistency with theseA
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detectable even in unstimulated cells. Similarly, when BMDCs were ex-
posed to increasing concentrations of CTLA4-Ig (up to 100 μg/ml), IDO
protein expression remained at the same level (Fig. 4C). Only upon ac-
tivation with LPS and IFN-γ, IDO protein expression became detectable
by immunoblotting (Fig. 4C). Remarkably, like in splenic DCs, despite
IDO expression at the protein level, IDO enzymatic activity remained
undetectable in BMDCs irrespective whether or not they were exposed
to CTLA4-Ig or stimulated with LPS/IFN-γ, as depicted by unchanged
tryptophan (Fig. 4D) and low kynurenine (not shown) concentrations
in cell culture supernatants after 24 h of stimulation. Thus, in this
model, CTLA4-Ig failed to induce IDO enzymatic activity in C57BL/6
splenic and BMDCs.
To address possible mechanisms for the divergence of IDO protein
expression without IDO enzymatic activity, we examined the produc-
tion of nitric oxide by BMDCs. Nitric oxide is known to inhibit IDO en-
zymatic activity [34] by interfering with the oxidation of the parent
IDO protein. We found that nitric oxide, as determined by the concen-
tration of nitrite, was enhanced in C57BL/6 BMDCs stimulated by LPS/
IFN-γ, suggesting that IDO activity in LPS/IFN-γ stimulated DCs ex-
pressing IDO protein was inhibited by the IDO competitor nitric
oxide (Fig. 4E).
3.4. CTLA4-Ig directly affects the interaction of stimulator and
responder cells
The aboveﬁndings did not support the concept of CTLA4-Ig inducing
a DC regulatory phenotype via IDO in this model. Therefore, in the next
series of experiments, we explicitly addressed the cellular mechanism
of CTLA4-Ig mediated immune regulatory activity by separating theA
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Fig. 5. CTLA4-Ig inhibits the allogeneic response stimulated by C57BL/6 splenic DCs or
BMDCs. (A) C57BL/6 splenic DCs were co-cultured with allogeneic CFSE labeled Balb/c
T cells at a 1:10 DC:T cell ratio in the absence or presence of CTLA4-Ig (100 μg/ml) for
6 days. T cells were identiﬁed as CD3+ cells and were analyzed for CD25 expression
and CFSE dilution (i.e. proliferation). Inserted numbers indicate the fraction of
CD25+CFSE− T cells. (B) Summary (mean±SEM) of three independently performed
experiments (as in A) in which splenic DCs (left) or BMDCs (right) were used as stim-
ulator cells. ***Pb0.001.interacting cell populations, DCs and T cells. First, we conﬁrmed that
C57BL/6 splenic as well as BMDCs were potent stimulators of allogeneic
Balb/c T cells. In fact, co-culturing splenic or BMDCs with allogeneic
highly enriched T cells in a 1:10 DC:T cell ratio resulted in a substantial
proliferative T cells response indicated by >70% CFSE negative T cells
after a 6 day co-culture (Fig. 5A, B).
Next, to demonstrate the inhibitory activity of CTLA4-Ig, we added
100 μg/ml CTLA4-Ig to co-cultures and, as expected, observed a ro-
bust inhibition of proliferation of 68%±5% (mean±SEM) in splenic
DCs (Pb0.001) (Fig. 5B, left) [35] and a slightly smaller inhibition
(45±5%) in BMDCs (Pb0.001) (Fig. 5B, right).
To address whether CTLA4-Ig speciﬁcally affects the stimulatory
function of DCs, we devised an experiment in which the DC population
was pre-exposed to CTLA4-Ig before being used for stimulating alloge-
neic T cells. In detail, C57BL/6 splenic DCs were exposed to CTLA4-Ig
for 24 h and thoroughly washed to remove unbound CTLA4-Ig; there-
after, DCs were co-cultured with Balb/c T cells in the absence of
CTLA4-Ig. Noticeably, a pre-exposure of DCs to CTLA4-Ig did not affect
their subsequent stimulatory capacity. Indeed, C57BL/6 splenic DCs in-
duced a comparable allogeneic T cell proliferative response (>70%
CFSE negative T cells), irrespective of whether DCs were left untreated
or pre-exposed to CTLA4-Ig (Fig. 6A). The same was observed when
BMDCs were pre-exposed to CTLA4-Ig and washed prior to co-culture
with allogeneic T cells (Fig. 6B, dotted line). Only when CTLA4-Ig was
present throughout DC/T cell co-cultures, the proliferative T cell re-
sponse to allogeneic stimulation was inhibited (Fig. 6B, solid line).B T cell exposure
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Fig. 6. CTLA4-Ig does not confer a DC regulatory phenotype but acts at the level of DC/T
cell interaction. (A) C57BL/6 splenic DCs were exposed to CTLA4-Ig (100 μg/ml, 24 h)
or maintained in medium only and washed prior to co-culture with allogeneic Balb/c
T cells. T cells were analyzed after 6 days of DC/T cell co-culture in the absence of
CTLA4-Ig. One representative of three experiments is shown. (B) BMDCs were exposed
to increasing concentrations of CTLA4-Ig for 24 h. Thereafter, DCs were washed and
co-cultured with allogeneic Balb/c T cells in the presence (black squares, solid line)
or absence (open circles, dashed line) of CTLA4-Ig for 6 days. T cells were analyzed
as in (A). One representative of three experiments is shown. (C) Puriﬁed Balb/c
CD3+ T cells were stimulated with plate bound anti-CD3/anti-CD28 for 48 h in the ab-
sence or presence of increasing concentrations of CTLA4-Ig. T-cell proliferation was
assessed by CFSE dilution. One representative of two experiments is shown.
644 E. Mayer et al. / International Immunopharmacology 15 (2013) 638–645To exclude that CTLA4-Ig affected the T cell response independently
of binding to DCs, we performed DC independent T cell proliferation
assays by stimulating T cells with plate-bound anti-CD3/anti-CD28
in the presence of increasing concentrations of CTLA4-Ig. In these exper-
iments, CTLA4-Ig did not reduce T cell proliferation even at high concen-
trations (200 μg/ml) of CTLA4-Ig (Fig. 6C). Furthermore, CTLA4-Ig did
not have a toxic effect on T cells as assessed by DAPI/Annexin V staining
(not shown). To examinewhether CTLA4-Ig induced IDO activity during
the course of the DC/T cell co-culture, we examined the concentrations
of tryptophan and kynurenine in cell culture supernatants at the end of
the MLR. The data did not indicate any tryptophan consumption or
kynurenine accumulation (Supplementary Table 1, S2), thus corrobo-
rating that immunoregulatory activity of CTLA4-Ig does not depend on
IDO activity.
In summary, our data indicated that CTLA4-Ig (i) rapidly
disappeared from the DC surface once removed from themicroenviron-
ment, (ii) failed to induce IDO activity and (iii) did not elicit a DC regu-
latory phenotype, but (iv) exerted suppressor activity at the level of DC/
T cell interaction.
4. Discussion
The present study focused particularly on the relevance of reverse
signaling for better understanding the immune regulatorymechanism
of CTLA4-Ig. In composite, our data do not support the view that re-
verse signaling is critical to CTLA4-Ig mediated immune regulation.
CTLA4-Ig has been originally developed based on the concept that
speciﬁc binding to CD80/CD86 molecules expressed on DCs interrupts
CD28 mediated signaling to T cells (reviewed in [4,6]) and thus can
propagate the emergence of anergy [36]. This effect of CTLA4-Ig has
been solidly evidenced in numerous in vitro and in vivo studies
[2,37,38]. The recently reported aspect of CTLA4-Ig activity – claiming
that CTLA4-Ig binding to CD80/86 transmits a signal back to DCs to
ultimately result in activation of the immunomodulatory IDO path-
way [10,11] – laid the basis for conceptualizing immunoregulatory
CTLA4-Ig to promote a DC regulatory phenotype in an IDO dependent
fashion. In their study, Grohmann et al. [10] found that IDO competence
was induced in DCs upon exposure to a CTLA4-Ig preparation in which
the CTLA-4 molecule was fused with IgG3 immunoglobulin tail in a
JAK-STAT1 dependent manner involving IFN-γ [32]. In a subsequent
study, Munn et al. found that IDO induction by CTLA4-Ig was restricted
to the B220+CD8α+DC subset and did not require IFN-γ for IDO induc-
tion [11]. Crediting CTLA4-Ig with the capability of inducing IDO via re-
verse signaling as a general mechanism has stimulated a controversial
debate. Pree et al. showed that CTLA4-Ig, while being essential for
the development of mixed chimerism in a murine model of non-
myeloablative bone marrow transplantation, did not involve trypto-
phan metabolism and its effect was not reversed by inhibition of IDO
[39]. In addition, several further murine and human studies reported
that the tolerogenic effect of CTLA4-Ig occurred without the involve-
ment of IDO [20,40]. Finally, microarray gene analysis of human imma-
ture and mature DCs exposed to two clinically probed CTLA4-Ig
compounds, abatacept or belatacept, failed to reveal any signiﬁcant
changes in gene expression, thus questioning the relevance of reverse
signaling of CTLA4-Ig to DCs [41].
In the present study, two lines of evidence stringently argue against
the concept of CTLA4-Ig inducing a DC regulatory phenotype via IDO.
(1) DCs exposed to CTLA4-Ig and washed prior to co-culture with allo-
geneic T cells were fully capable of stimulating T cell proliferation. Upon
removal from the microenvironment, CTLA4-Ig disappeared rapidly
from the DC membrane and thereafter had no enduring effect on the
DC stimulatory capacity, which would be expected if DCs acquired reg-
ulatory activity from CTLA4-Ig mediated reverse signaling. (2) The ex-
plicit examination of DC IDO activity failed to generate evidence that
CTLA4-Ig induced tryptophan breakdown. The only slight induction of
IFN-γ by CTLA4-Ig in splenic DCs [32] was not reproducible in BMDCs.Apparently, CTLA4-Igwas unable to induce IDO activity or any other im-
mune regulatory effect in both DC populations. Of note, the pharmaco-
logically designed CTLA4-Ig fusion protein, abatacept, containing a
human IgG1 Fc-portion was used throughout the hereby presented ex-
periments. In addition, the testing of a recombinant mouse cytolytic
CTLA4-Ig (IgG2a, Sigma) fusion protein gave the same results (data
not shown). This indicates that the absence of reverse signaling by
CTLA4-Ig in this study was not related to the different IgG portions
(IgG1, IgG2a) of the CTLA4-Ig fusion protein.
The problem of discrepant ﬁndings in the various studies address-
ing an association of CTLA4-Ig and IDO induction remains unsolved at
this point. States of IDO expression on an mRNA and protein level
without concomitant tryptophan metabolizing activity have been de-
scribed. These states are particularly associated with alterations of the
post-translational modiﬁcations, i.e. the oxidation of the ferric to the
ferrous form of the heme moiety of IDO which is essential to initiate
IDO enzymatic activity [17,34]. Nitric oxide is known as an important
inhibitor of IDO enzymatic activity and may contribute to the failure
of murine LPS/IFN-γ-stimulated C57BL/6 CD11c+ DCs to exhibit IDO
enzymatic activity as we observed in this study [34]. As well, seem-
ingly trivial differences in experimental procedures or CTLA4-Ig prep-
arations or in utilizing different DC:T cell ratios in the MLR may
underlie the discrepancies, as recently discussed [25,42,43].
From our ﬁndings, we conclude that CTLA4-Ig is not effective in
generating regulatory DCs but exerts potent immunoregulatory activ-
ity by affecting the DC/T cell crosstalk. This conclusion has a major
implication for designing immunoregulatory cell therapies. CTLA4-Ig
apparently has no durable effect on DCs, implying that CTLA4-Ig ex-
posed DCs cannot be expected to display immune regulatory activity
upon adoptive transfer. Rather, the efﬁcacy of CTLA4-Ig blocking the
CD28:CD80/86 pathway for the generation of T cell anergy can be
exploited by co-culturing T cells with APCs in the continuous pres-
ence of CTLA4-Ig ex vivo prior to adoptive transfer of anergic T cells,
as has been recently described [44].
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